Answers are grounded in this paper and cite their sources.
Cytotoxic T cells in the blood of patients with PDAC remain sensitive to reinvigoration by PD-1 blockade, and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti-PD-1 reinvigoration and marks these T cells as non-productive contributors to antitumor immunity. See related commentary by Lander and DeNardo, p. 474.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: